Evidence for immunosuppression in lung transplantation

Current Opinion in Organ Transplantation

Volumn 13, Issue 5, 2008, Pages 477-483

  Hopkins, Peter M ^a   McNeil, Keith ^a  

^a THE PRINCE CHARLES HOSPITAL   (Australia)

Author keywords

Acute rejection; Immunosuppression; Lung transplantation

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; EVEROLIMUS; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHOTREXATE; METHOXSALEN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISOLONE; PREDNISONE; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; ANTIMETABOLITE; CALCINEURIN; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN; MONOCLONAL ANTIBODY; PROTEIN KINASE; PROTEIN KINASE INHIBITOR;

ACUTE GRAFT REJECTION; BACTERIAL INFECTION; BRONCHIOLITIS; BRONCHIOLITIS OBLITERANS; CARDIAC GRAFT REJECTION; CHRONIC GRAFT REJECTION; CLINICAL PRACTICE; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG PULSE THERAPY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY GRAFT REJECTION; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; LYMPH NODE IRRADIATION; METHODOLOGY; NONHUMAN; OPPORTUNISTIC INFECTION; PHOTOCHEMOTHERAPY; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SINGLE DRUG DOSE; ACUTE DISEASE; ANIMAL; CHRONIC DISEASE; DRUG ANTAGONISM; DRUG COMBINATION; IMMUNOLOGY; METABOLISM; RECURRENT DISEASE;

ACUTE DISEASE; ADRENAL CORTEX HORMONES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIMETABOLITES; CALCINEURIN; CHRONIC DISEASE; DRUG THERAPY, COMBINATION; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; RECURRENCE;

EID: 60849121146     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32831040bf     Document Type: Review

References (56)

1. King-Biggs MB. Acute pulmonary allograft rejection: mechanisms, diagnosis and management. Clin Chest Med 1997; 18:301-310.
2. Charpentier B, Hiesse C, Durrbach A, et al. Immunosuppression advancing in the new millennium: lessons learned from recent multicentre and single centre clinical trials. Curr Opin Organ Transplant 2000; 5:249-254.
3. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7:145-173.
4. Nickerson P, Steurer W, Steiger J. Cytokines and the Th1/Th2 paradigm in transplantation. Curr Opin Immunol 1994; 6:757-764.
5. Hopkins PM, Aboyoun CL, Chhajed PN, et al. Prospective analysis of 1235 transbronchial lung biopsies in lung transplant recipients. J Heart Lung Transplant 2002; 21:1062-1067.
6. Starzl TE, Porter KA, Iwasaki Y. The use of heterologous antilymphocyte globulins in human homotransplantation. In: Wolstenholme GEW, O'Connor M, editors. Antilymphocyte serum. Boston: Little, Brown; 1967. p. 1.
7. Rebellato LM, Gross U, Verbanac KM. A comprehensive definition of the major antibody specificities in polyclonal rabbit antithymocyte globulin. Transplantation 1994; 57:685-694.
8. Bourdage JS, Hamlin DM. Comparative polyclonal antithymocyte globulin and antilymphocyte/antilymphoblast globulin anti-CD antigen analysis by flow cytometry. Transplantation 1995; 59:1194-1200.
9. Cosimi AB, Burton RC, Colvin RB. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 1981; 32:535.
10. Bonnefoy-Berard N, Revillard JP. Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. J Heart Lung Transplant 1996; 15:435-442.
11. Wechter WJ, Broodie JA, Morrell RM. Antithymocyte globulin (ATGAM) in renal allograft recipients. Transplantation 1979; 28:294-307.
12. Cosimi AB. The clinical value of antilymphocyte antibodies. Transplant Proc 1981; 13:462-468.
13. Klepetko W, Jaksch P, Kocher AA, et al. Prospective, randomised trial comparing induction therapy with daclizumab or rabbit antithymocyte globulin versus no induction therapy after lung transplantation. J Heart Lung Transplant 2002; 21:A33.
14. Hartwig MG, Snyder LD, Appel JZ, et al. Rabbit antithymocyte globulin induction therapy does not prolong survival after lung transplantation. J Heart Lung Transplant 2008; 27:547-553.
15. George JF. In: Kirklin JK, Young JB, McGiffin DC, editors. Immunosuppressive modalities in heart transplantation. New York: Churchill Livingstone; 2002. pp. 390-462.
16. Cantarovich M,Metrakos P, Giannette N, et al. Anti-CD25 monoclonal antibody coverage allows for calcineurin inhibitor 'holiday' in solid organ transplant patients with acute renal dysfunction. Transplantation 2002; 73:1169-1172.
17. BrockMV, Borja MC, Ferber L, et al. Induction therapy in lung transplantation: a prospective controlled clinical trial comparing OKT3, antithymocyte globulin and daclizumab. J Heart Lung Transplant 2001; 20:1282-1290.
18. Hachem RR, Edwards LB, Yusen RD, et al. The impact of induction on survival after lung transplantation: an analysis of the International Society of Heart and Lung Transplantation Registry. Clin Transplant 2008. [Epub ahead of print]
19. Burton CM, Anderson CB, Jensen AS, et al. The incidence of acute cellular rejection after lung transplantation: a comparative study of antithymocyte globulin and daclizumab. J Heart Lung Transplant 2006; 25:638-647.
20. Ailawadi G, Smith PW, OkaT, et al. Effects of induction immunosuppression regimen on acute rejection, bronchiolitis obliterans, and survival after lung transplantation. J Thorac Cardiovasc Surg 2008; 135:594-602.
21. Charpentier B, Hiesse C, Durrbach A, et al. Immunosuppression advancing in the new millennium: lessons learned from recent multicentre and single centre clinical trials. Curr Opin Organ Transplant 2000; 5:249-254.
22. Calne RY, White DJ, Thiru S, et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 1978; 2:1323-1327.
23. Todo S, Fung JJ, Tzakis A, et al. One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. Transplant Proc 1991; 23:1397-1402.
24. Briffa N, Morris RE. New immunosuppressive regimens in lung transplantation. Eur Respir J 1997; 10:2630-2637.
25. Baz MA, Layish D, Govert JA, et al. Diagnostic yield of bronchoscopies after isolated lung transplantation. Chest 1996; 110:84-88.
26. Hachem R, Yusen RD, Chakinala MM, et al. A randomised, controlled trial of tacrolimus versus cyclosporine after lung transplantation. J Heart Lung Transplant 2007; 26:1012-1018.
27. Reichenspurner H,Glanville A, Aboyoun C, et al. Complete 3 year analysis of a prospective randomised international multicentre investigator driven study comparing tacrolimus and cyclosporin A, both in combination with MMF and steroids after lung transplantation in 249 patients. J Heart Lung Transplant 2008; 27:A402.
28. Sollinger H, Deierhoi M, Belzer F, et al. RS- 61443: a phase I clinical trial and pilot rescue study. Transplantation 1992; 53:428-432.
29. European Mycophenolate Mofetil Cooperative Study Group. Placebocontrolled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345:1321 -1325.
30. Kung L, Gourishankar S, Halloran P. Molecular pharmacology of immunosuppressive agents in relation to their clinical use. Curr Opin Organ Transplant 2000; 5:268-275.
31. Rayhill SC, Sollinger H. Mycophenolate mofetil: experimental and clinical experience. In: Ginns LC, Cosimi AB, Morris P, editors. Immunosuppression in transplantation. Malden: Blackwell Science Inc; 1999 . pp. 47-66.
32. McNeil K, Glanville A, Wahlers T, et al. Comparison of mycophenolate mofetil and azathioprinefor prevention of bronchiolitis obliterans syndrome in de novo lung transplant recipients. Transplantation 2006; 81:998-1003.
33. Nashan B. Review of the proliferation inhibitor everolimus. Expert Opin Investig Drugs 2002; 11:1845-1857.
34. Snell G, Valentine V, Vitulo P, et al. Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomised, double-blind clinical trial. Am J Transplant 2006; 6:169-177.
35. Strueber M, Stefan F, Simon A, et al. Everolimus versus mycophenolate in de novo immunosuppression after lung transplantation: interim analysis of a prospective, randomized clinical trial. J Heart Lung Transplant 2008; 27:A401.
36. Orta-Sibu N, Chantler C, Bewick M, et al. Comparison of high-dose intravenous methylprednisolone with low-dose oral prednisolone in acute renal allograft rejection in children. Br Med J 1982; 285:258-260.
37. Park M, Starling R, Ratliff N, et al. Oral steroid pulse without taper for the treatment of asymptomatic moderate cardiac allograft rejection. J Heart Lung Transplant 1999; 18:1224-1227.
38. Hopkins P, Aboyoun C, Chhajed P, et al. Association of minimal acute rejection in lung transplant recipients with obliterative bronchiolitis. Am J Respir Crit Care Med 2004; 170:1022-1026.
39. Clelland C, HigenbottamT, Otulana B, et al. Histologic prognostic indicators for the lung allografts of heart-lung transplants. J Heart Lung Transplant 1990; 9:1 77-186.
40. Tanizaki Y, Kitani H, Mifune T, et al. Effects of glucocorticoids on humoral and cellular immunity and on airway inflammation in patients with steroiddependant intractable asthma. J Asthma 1993; 30:485-492.
41. Schuyler M, Bondarevsky E, Schwartz H, et al. Corticosteroid- sensitive lymphocytes are normal in atopic asthma. J Allergy Clin Immunol 1981; 68:72-78.
42. Cantarovich M, Latter D, Loertscher R. Treatment of steroid-resistant and recurrent acute cardiac transplant rejection with a short course of antibody therapy. Clin Transplant 1997; 11:316-321.
43. The Mycophenolate Mofetil Renal Refractory Rejection Study Group. Mycophenolate mofetil for the treatment of refractory, acute cellular renal transplant rejection. Transplantation 1996; 61:722-729.
44. Mentzer R, Jahania M, Lasley R. Tacrolimus as a rescue immunosuppressant after heart and lung transplantation. The US Multicentre FK506 Study Group. Transplantation 1998; 65:109-113.
45. De Bonis M, Reynolds L, Barros J, et al. Tacrolimus as a rescue immunosuppressant after heart transplantation. Eur J Cardiothorac Surg 2001; 19:690-695.
46. Onsager D, CanverC, Jahania M, et al. Efficacy of tacrolimus in the treatment of refractory rejection in heart and lung transplant recipients. J Heart Lung Transplant 1999; 18:448-455.
47. Jiang H, Wynn C, Pan F, et al. Tacrolimus and cyclosporin differ in their capacity to overcome ongoing allograft rejection as a result of their differential abilities to inhibit interleukin-10 production. Transplantation 2002; 73:1808-1817.
48. Cahill B, O'Rourke M, Strasburg K, et al. Methotrexate for lung transplant recipients with steroid-resistant acute rejection. J Heart Lung Transplant 1996; 15:1130-1137.
49. Boettcher H, Costard-Jackle A, Moller F, et al. Methotrexate as rescue therapy in lung transplantation. Transplant Proc 2002; 34:3255-3257.
50. Keenan R, Iacono A, Dauber J, et al. Treatment of refractory acute allograft rejection with aerosolized cyclosporin in lung transplant recipients. J Thorac Cardiovasc Surg 1997; 113:335-340.
51. Iacono A, Smaldone G, Keenan R, et al. Dose related reversal of acute lung rejection by aerosolized cyclosporin. Am J Respir Crit Care Med 1997; 155:1690-1698.
52. Chen H, Wu J, Xu D, et al. Reversal of ongoing heart, kidney and pancreas allograft rejection and suppression of accelerated heart allograft rejection in the rat by rapamycin. Transplantation 1993; 56:661-666.
53. Hong J, Kahan B. Sirolimus rescue therapy for refractory rejection in renal transplantation. Transplantation 2001; 71:1579-1584.
54. Valentine V, Robbins R, Wehner J, et al. Total lymphoid irradiation for refractory acute rejection in heart-lung and lung allografts. Chest 1996; 109: 1184-1189.
55. Dall'Amico R, Murer L. Extracorporeal photochemotherapy: a new therapeutic approach for allograft rejection. Transfus Apher Sci 2002; 26:197-204.
56. Villanueva J, Bhorade S, Robinson J, et al. Extracorporeal photopheresis for the treatment of lung allograft rejection. Ann Transplant 2000; 5:44-47.